Author: Lumanity

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

May 21, 2026
Lumanity Launches EMULaiTOR™, an AI-Powered Synthetic Persona Platform Transforming Stakeholder Engagement in Life Sciences

March 5, 2026

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer